L. Provencher

发表

Tissue Microarray Is a Reliable Tool for the Evaluation of HER2 Amplification in Breast Cancer.

F. Sanschagrin, C. Diorio, D. Furrer, 2016, Anticancer research.

Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer.

G. Pond, D. Coyle, A. Robidoux, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Incidence of scalp metastases in breast cancer: a retrospective cohort study in women who were offered scalp cooling

E. Maunsell, L. Provencher, J. Lemieux, 2009, Breast Cancer Research and Treatment.

Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.

M. Clemons, T. Vandenberg, D. Rayson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Eligibility criteria in randomized phase II and III adjuvant and neoadjuvant breast cancer trials: Not a significant barrier to enrollment

Catherine Doyle, Christine Desbiens, Louise Provencher, 2012, Clinical trials.

Evaluation of eligibility and recruitment in breast cancer clinical trials.

G. Forget, S. Camden, B. Poirier, 2014, Breast.

Evaluation of Factors Associated with Recruitment in Breast Cancer Clinical Trials in a Specialized Breast Cancer Centre.

G. Forget, S. Camden, J. Robert, 2009 .

Validation of a new classifier for the automated analysis of the human epidermal growth factor receptor 2 (HER2) gene amplification in breast cancer specimens

Caroline Diorio, Louise Provencher, F. Sanschagrin, 2013, Diagnostic Pathology.

Chemotherapy‐induced alopecia and effects on quality of life among women with breast cancer: a literature review

Louise Provencher, E. Maunsell, Julie Lemieux, 2008, Psycho-oncology.

Abstract S3-02: NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients (pts) with node-negative breast cancer

T. Julian, C. Geyer, D. Wickerham, 2015 .

Hypofractionated radiation therapy for breast ductal carcinoma in situ.

M. Yassa, H. Bahig, H. Vulpe, 2013, International journal of radiation oncology, biology, physics.

Do Preoperative Prophylactic Antibiotics Reduce Surgical Site Infection Following Wire-Localized Lumpectomy? A Single-Blind Randomized Clinical Trial

B. Poirier, L. Provencher, J. Hogue, 2021, Annals of Surgical Oncology.

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

D. Miles, L. Dirix, G. Romieu, 2013, British Journal of Cancer.

Is contralateral breast ultrasound worthwhile in preoperative staging of breast cancer?

L. Provencher, J. Hogue, N. Duchesne, 2019, Journal of clinical ultrasound : JCU.

Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer

M. Buyse, J. Mackey, N. Robert, 2013 .

Immunohistochemistry of Breast Tumor Markers on Archived Bouin-fixed Paraffin-embedded Tissues

J. Gagnon, F. Sanschagrin, C. Diorio, 2011, Applied immunohistochemistry & molecular morphology : AIMM.

Validation of EP1 Antibody Clone for Estrogen Receptor Immunohistochemistry for Breast Cancer.

C. Diorio, D. Furrer, Simon Jacob, 2016, Anticancer research.

Characteristics associated with upgrading to invasiveness after surgery of a DCIS diagnosed using percutaneous biopsy.

B. Poirier, C. Diorio, Simon Jacob, 2014, Anticancer research.

Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.

M. Piccart, G. Hortobagyi, J. Baselga, 2013, European journal of cancer.

Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy

S. Luoh, G. Hortobagyi, L. Vahdat, 2010, Breast Cancer Research and Treatment.

Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.

S. Paik, G. Tang, J. Costantino, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BCIRG 005 main efficacy analysis: a phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC->T) in women with Her-2/neu negative axillary lymph node positive early breast cancer.

M. Buyse, G. Sauter, J. Mackey, 2009 .

Women with breast cancer’s perceptions of nurse-led telephone-based motivational interviewing consultations to enhance adherence to adjuvant endocrine therapy: a qualitative study

Myriam E Gagné, S. Lauzier, C. Loiselle, 2022, Supportive Care in Cancer.

Correlation of molecular alterations with efficacy of everolimus in hormone-receptor-positive, HER2-negative advanced breast cancer: Results from BOLERO-2.

G. Hortobagyi, J. Baselga, M. Campone, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of Hypericum perforatum (St. John's wort) on hot flashes and quality of life in perimenopausal women: a randomized pilot trial

R. Verreault, E. Maunsell, L. Provencher, 2009, Menopause.

Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement.

K. Gelmon, S. Verma, K. Pritchard, 2013, Current oncology.

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

Arlene Chan, Andreas Schneeweiss, Luc Y Dirix, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study

T. Julian, C. Geyer, N. Wolmark, 2014, Breast Cancer Research and Treatment.

Comparison of Serious Adverse Events Between the Original and a Generic Docetaxel in Breast Cancer Patients

I. Côté, B. Poirier, L. Provencher, 2014, The Annals of pharmacotherapy.

Impact of the 21-Gene Recurrence Score Assay on Treatment Decisions and Cost in Patients with Node-Positive Breast Cancer: A Multicenter Study in Quebec

A. Robidoux, M. Guertin, L. Sidéris, 2022, The oncologist.

Prognostic and predictive value of low estrogen receptor expression in breast cancer.

C. Blanchette, C. Diorio, L. Provencher, 2017, Current oncology.

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.

M. Buyse, G. Sauter, J. Mackey, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)

T. Julian, C. Geyer, P. Ward, 2021, Breast Cancer Research and Treatment.

How Wide Should Margins Be for Phyllodes Tumors of the Breast?

B. Poirier, C. Diorio, L. Provencher, 2017, The breast journal.

DNA Methylation and Breast Cancer Risk: An Epigenome-Wide Study of Normal Breast Tissue and Blood

K. Ennour-Idrissi, C. Diorio, L. Provencher, 2020, Cancers.

Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: Results from BOLERO-2.

J. Baselga, H. Rugo, M. Campone, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Factors associated with upgrading to malignancy at surgery of atypical ductal hyperplasia diagnosed on core biopsy.

J. Robert, B. Poirier, C. Diorio, 2011, Breast.

Is there an Upgrading to Malignancy at Surgery of Mucocele‐Like Lesions Diagnosed on Percutaneous Breast Biopsy?

B. Poirier, C. Diorio, Simon Jacob, 2016, The breast journal.

Abstract P3-12-01: Impact of treatment on quality of life (QOL) and menstrual history (MH) in the NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide

E. Perez, N. Wolmark, P. Ward, 2015 .

Adjuvant docetaxel for node-positive breast cancer.

Marek Pawlicki, John Hainsworth, Matthieu Rupin, 2005, The New England journal of medicine.

Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer

A. Schneeweiss, M. Parmar, J. Mackey, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Paraneoplastic Encephalomyelitis, Stiff Person Syndrome and Breast Carcinoma

D. Brunet, L. Provencher, J. Hogue, 2011, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

S4-8: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2−positive locally recurrent/metastatic breast cancer (LR/mBC)

R. Greil, F. André, V. Semiglazov, 2011 .

Pegylated liposomal doxorubicin (PLD) plus cyclophosphamide as 1st-line therapy for metastatic breast cancer in patients previously treated with anthracyclines

T. Vandenberg, D. Rayson, M. Trudeau, 2005 .

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.

P. Neven, M. Piccart, G. Hortobagyi, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2.

S. Paik, J. Costantino, C. Geyer, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer

B. Knoppers, B. Godard, D. Easton, 2006, Journal of Medical Genetics.

Insomnia, immunity, and infections in cancer patients: Results from a longitudinal study.

C. Morin, J. Savard, C. Bastien, 2019, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

No Evidence of BRCA 1 / 2 Genomic Rearrangements in High-Risk French-Canadian Breast / Ovarian Cancer Families

M. Dumont, J. Simard, D. Goldgar, 2009 .

No Evidence of BRCA1/2 genomic rearrangements in high-risk French-Canadian breast/ovarian cancer families.

M. Dumont, J. Simard, D. Goldgar, 2006, Genetic testing.

A new alternative splice variant of BRCA1 containing an additional in-frame exon.

M. Dumont, J. Simard, Y. Labrie, 2005, Biochimica et biophysica acta.

Low frequency of cancer occurrence in same breast quadrant diagnosed with lobular neoplasia at percutaneous needle biopsy.

I. Raiche, B. Poirier, C. Diorio, 2012, Radiology.

Selection of adjuvant chemotherapy for treatment of node-positive breast cancer.

K. Gelmon, J. Mackey, K. Pritchard, 2005, The Lancet. Oncology.

Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion

L. Rosen, R. Coleman, J. Simeone, 2004, Cancer.

Validation of EP1 Antibody Clone for Estrogen Receptor Immunohistochemistry in Breast Cancer

F. Sanschagrin, C. Diorio, Chantal Caron, 2014, Applied immunohistochemistry & molecular morphology : AIMM.

Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.

M. Buyse, G. Sauter, J. Mackey, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Correlation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2.

G. Hortobagyi, J. Baselga, H. Rugo, 2013 .

Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study.

M. Brackstone, L. Gaboury, A. Robidoux, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey.

S. Verma, R. Dent, L. Provencher, 2011, Current oncology.

Comparative Efficacy and Safety of Controlled‐Release Morphine Suppositories and Tablets in Cancer Pain

D. Moulin, F. Laberge, L. Provencher, 1998, Journal of clinical pharmacology.

Recommendations on breast cancer screening and prevention in the context of implementing risk stratification: impending changes to current policies.

B. Knoppers, W. Foulkes, S. Meterissian, 2016, Current oncology.

Quantitative exploration of possible reasons for the recent improvement in breast cancer survival

T. Duchesne, J. Brisson, N. Hébert-croteau, 2007, Breast Cancer Research and Treatment.

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.

J. Mackey, W. Eiermann, T. Pintér, 2011, The Lancet. Oncology.

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer

P. Neven, R. Bose, H. Rugo, 2021, Breast Cancer Research and Treatment.

Survival Rate of Breast Cancer Patients who Participated in Clinicals Trials Versus those who did not

T. Duchesne, J. Brisson, C. Blanchette, 2014 .

Aromatase inhibitors in obese breast cancer patients are not associated with increased plasma estradiol levels

C. Diorio, L. Provencher, J. Hogue, 2012, Breast Cancer Research and Treatment.

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.

M. Dowsett, T. Julian, M. Cheang, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Characteristics and long‐term survival of patients diagnosed with pure tubular carcinoma of the breast

B. Poirier, C. Diorio, Simon Jacob, 2018, Journal of surgical oncology.

Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab.

Caroline Diorio, Louise Provencher, F. Barabé, 2013, Anticancer research.

Evaluation of human epidermal growth factor receptor 2 (HER2) single nucleotide polymorphisms (SNPs) in normal and breast tumor tissues and their link with breast cancer prognostic factors.

F. Barabé, C. Diorio, D. Furrer, 2016, Breast.

Association of Tobacco Use, Alcohol Consumption and HER2 Polymorphisms With Response to Trastuzumab in HER2‐Positive Breast Cancer Patients

C. Diorio, D. Furrer, Simon Jacob, 2017, Clinical breast cancer.

Safety of bevacizumab (BV) plus docetaxel (D) in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) who developed brain metastases during the AVADO phase III study.

D. Miles, L. Mauriac, L. Dirix, 2009 .

Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer

E. Perez, C. Geyer, P. Ward, 2022, Breast Cancer Research and Treatment.

Quantitative DNA methylation analysis of laser capture microdissected formalin-fixed and paraffin-embedded tissues.

J. Gagnon, F. Sanschagrin, J. Robert, 2010, Experimental and molecular pathology.

Optimizing the management of HER2-positive early breast cancer: the clinical reality.

J. Mackey, S. Chia, M. Clemons, 2010, Current oncology.

Practice Guideline Series

J. Mackey, S. Chia, M. Clemons, 2022 .

The role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer

J. Mackey, S. Verma, M. Clemons, 2009, Current oncology.

Adjuvant Docetaxel plus Doxorubicin and Cyclophosphamide for Node-Positive Breast Cancer

A. Howell, J. Hainsworth, J. Mackey, 2005 .

Out-of-pocket costs in the year after early breast cancer among Canadian women and spouses.

D. Coyle, A. Robidoux, S. Lauzier, 2013, Journal of the National Cancer Institute.

Concordance of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization Using Tissue Microarray in Breast Cancer.

F. Sanschagrin, C. Diorio, D. Furrer, 2017, Anticancer research.

Does breast cancer tumor size really matter that much?

C. Diorio, Simon Jacob, L. Provencher, 2012, Breast.

Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group

J. Mackey, M. Sawyer, S. Verma, 2008, Current oncology.

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.

J. Hainsworth, J. Mackey, D. Walde, 2013, The Lancet. Oncology.

Psychological distress and physical health in the year after diagnosis of DCIS or invasive breast cancer

A. Robidoux, S. Lauzier, E. Maunsell, 2010, Breast Cancer Research and Treatment.

Results of a multicenter randomized trial to evaluate a survivorship care plan for breast cancer survivors.

G. Pond, A. Robidoux, K. Pritchard, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Activity and safety of the antiestrogen EM-800, the orally active precursor of acolbifene, in tamoxifen-resistant breast cancer.

J. Roy, C. Labrie, M. Pollak, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant targeted therapy in early breast cancer

K. Gelmon, J. Mackey, J. Ragaz, 2009, Cancer.

Validating the content of a brief informational intervention to empower patients and spouses facing breast cancer: perspectives of both couple members

A. Robidoux, S. Guay, S. Lauzier, 2014, Journal of Cancer Survivorship.

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor – Positive Early Breast Cancer

Maggie, Morden., M. Dowsett, 2019 .

Wage losses among spouses of women with nonmetastatic breast cancer

D. Coyle, A. Robidoux, S. Lauzier, 2019, Cancer.

Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.

S. Chia, K. Pritchard, D. Rayson, 2017, The oncologist.

Women’s Beliefs on Early Adherence to Adjuvant Endocrine Therapy for Breast Cancer: A Theory-Based Qualitative Study to Guide the Development of Community Pharmacist Interventions

S. Lauzier, J. Moisan, L. Guillaumie, 2018, Pharmacy.

Patterns of confidant use among patients and spouses in the year after breast cancer

A. Robidoux, S. Guay, S. Lauzier, 2009, Journal of cancer survivorship : research and practice.

Is clinical breast examination important for breast cancer detection?

J. Chiquette, B. Poirier, C. Diorio, 2016, Current oncology.

Development of a community pharmacy-based intervention to enhance adherence to adjuvant endocrine therapy among breast cancer survivors guided by the Intervention Mapping approach.

H. Nabi, S. Lauzier, L. Guillaumie, 2020, Research in social & administrative pharmacy : RSAP.

Prospective cohort study of chemotherapy-induced alopecia with or without scalp cooling.

S. Lauzier, B. Abdous, E. Maunsell, 2012 .

P. Neven, M. Piccart, G. Hortobagyi, 2013, Current medical research and opinion.

Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial.

H. Wildiers, D. Richel, J. Canon, 2012, Annals of Oncology.

No effect of scalp cooling on survival among women with breast cancer

J. Brisson, C. Blanchette, E. Maunsell, 2014, Breast Cancer Research and Treatment.

Identifying Clinicopathological Factors Associated with Oncotype DX® 21-Gene Recurrence Score: A Real-World Retrospective Cohort Study of Breast Cancer Patients in Quebec City, Canada

H. Nabi, C. Diorio, L. Provencher, 2021, Journal of personalized medicine.

Extending neoadjuvant care through multi-disciplinary collaboration: proceedings from the fourth annual meeting of the Canadian Consortium for Locally Advanced Breast Cancer.

M. Brackstone, M. Untch, S. Chia, 2012 .

RE: Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424).

H. Nabi, C. Diorio, L. Provencher, 2018, Journal of the National Cancer Institute.

Comparison of hydromorphone continuous subcutaneous infusion and basal rate subcutaneous infusion plus PCA in cancer pain: a pilot study

É. Poulin, M. Vanier, L. Provencher, 1993, Pain.

THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

D. Brunet, L. Provencher, J. Lemieux, 2014 .

Abstract P2-16-04: Plasma Biomarker Analyses in the AVADO Phase III Randomized Study of First-Line Bevacizumab + Docetaxel in Patients with Human Epidermal Growth Factor Receptor (HER) 2-Negative Metastatic Breast Cancer

D. Miles, L. Dirix, X. Pivot, 2010 .

The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers

D. Rayson, L. Provencher, B. Wang, 2009, Current oncology.

Phase II study of sagopilone (ZK-Epo) in patients with recurrent metastatic breast cancer (MBC).

S. Luoh, G. Hortobagyi, L. Vahdat, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.